Bimatoprost grenod
Based on 1 Customer Validation
Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.41%
- CAS No.: 1194396-71-8
- Formule: C31H46N2O8
- Masse moléculaire:574.71
-
Stockage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-14648A
Dexamethasone acetateCorticosteroid Ester -
HY-14648AR
Dexamethasone acetate (Standard)Analytical Standard -
HY-113481
Prostaglandin E3Prostaglandin Analog -
HY-135750
VAF347AhR Agonist -
HY-159704
9-Keto-latanoprostLatanoprost Derivative -
HY-125774
Bimatoprost acidProstaglandin FP Receptor Agonist -
HY-130660
Prostaglandin F2α ethanolamideEndogenous Hormone -
HY-118648
Prostaglandin F2α methyl esterIOP Lowering Agent -
HY-106037
PGF2α-isopropyl esterIOP Reducing Agent -
HY-B0191B
Bimatoprost methyl esterBimatoprost Prodrug -
HY-B0191C
N-Desethyl BimatoprostBimatoprost Metabolite -
HY-124243
N-Cyclopropyl methyl bimatoprostFP Receptor Agonist
Activité biologique
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:New Zealand white rabbits with 0.1 mL 5% sodium chloride solution injection[2]
-
Dosage:0.14%
-
Administration:Instillation; 0.14% 30 μL; once
-
Result:Significantly blunted the IOP rise throughout the experimental period in transiently ocular hypertensive New Zealand white rabbits.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1194396-71-8
-
Appearance Oil
-
Masse moléculaire 574.71
-
Formule C31H46N2O8
-
Color Colorless to light yellow
-
SMILES
O=C(O[C@@H](CCC1=CC=CC=C1)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(NCC)=O)[C@@H](O)C[C@H]2O)CCCCCO[N+]([O-])=O
-
Synonyms
NCX 470
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (174.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Impagnatiello F, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019 Apr;176(8):1079-1089. [Content Brief]
[2]. Impagnatiello F, et al. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6558-64. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7400 mL | 8.7000 mL | 17.4001 mL | 43.5002 mL |
| 5 mM | 0.3480 mL | 1.7400 mL | 3.4800 mL | 8.7000 mL | |
| 10 mM | 0.1740 mL | 0.8700 mL | 1.7400 mL | 4.3500 mL | |
| 15 mM | 0.1160 mL | 0.5800 mL | 1.1600 mL | 2.9000 mL | |
| 20 mM | 0.0870 mL | 0.4350 mL | 0.8700 mL | 2.1750 mL | |
| 25 mM | 0.0696 mL | 0.3480 mL | 0.6960 mL | 1.7400 mL | |
| 30 mM | 0.0580 mL | 0.2900 mL | 0.5800 mL | 1.4500 mL | |
| 40 mM | 0.0435 mL | 0.2175 mL | 0.4350 mL | 1.0875 mL | |
| 50 mM | 0.0348 mL | 0.1740 mL | 0.3480 mL | 0.8700 mL | |
| 60 mM | 0.0290 mL | 0.1450 mL | 0.2900 mL | 0.7250 mL | |
| 80 mM | 0.0218 mL | 0.1088 mL | 0.2175 mL | 0.5438 mL | |
| 100 mM | 0.0174 mL | 0.0870 mL | 0.1740 mL | 0.4350 mL |
Bimatoprost grenod Related Classifications
HY-139419 Related Classifications
Powered by Bioz